Sentences with phrase «from immune therapies»

The answer to increasing the effectiveness of immune therapies, or perhaps at least to choosing which patients are most likely to benefit from immune therapies, may lie in understanding the ways viruses (and cancers themselves) have evolved to evade the immune system.

Not exact matches

There are more than 80 immune - related cancer therapies currently in clinical trials, fueled by many billions of dollars in pharmaceutical investment from the likes of Bristol - Myers Squibb bmy, Merck mrk, Pfizer pfe, and dozens of biotechs.

Bone loss in HIV infection is due to immune dysregulation, chronic inflammation and antiretroviral therapy, as well as increased bone turnover from the HIV - infection itself.

In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors showed fewer chromosomal disruptions.

«Steep funding cuts for the federal health agencies are counterproductive at a time when innovative research is moving us closer to identifying solutions for rare diseases, new prevention strategies to protect Americans from deadly and costly conditions, advances in gene therapy, new technologies for understanding the brain, and treatments that harness the ability of our immune system to fight cancer.»

And early stage startup Neochromosome, which includes Boeke, intends to raise money to design synthetic chromosomes for medicine that could be used in an off - the - shelf universal cell line in cell therapies and transplants with minimal risk of rejection from the immune system.

Researchers are developing many different versions of CAR - T cell therapies, but the basic premise is the same: Doctors remove a patient's T cells (immune system cells that attack invaders) from a blood sample and genetically modify them to produce artificial proteins on their surfaces.

Then immunotherapy firm Juno Therapeutics shook hands with gene - editing start - up Editas to create anticancer immune cell therapies; Vertex Pharmaceuticals and Crispr Therapeutics, another start - up, inked an agreement that could be valued at $ 2.6 billion; while Regeneron Pharmaceuticals formed a patent licence agreement with ERS Genomics, which holds the rights to the foundational Crispr intellectual property from Emmanuelle Charpentier, one of the Crispr pioneers.

Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.

At the moment a lot of therapies are focused on the site of infection or injury itself but this data suggests that it's the signals that are being sent out from the gut that are impacting the whole immune system.

Instead, the therapy may benefit from the activity of the immune system operating in tandem, creating a synergistic, cancer - killing effect.

Sources within MMCAR, a research consortium of scientists from the US armed forces and the Henry Jackson Foundation, say there is no evidence that the MicroGeneSys vaccine works as an immune therapy.

The technical advances emerging from gene therapy have fueled the larger fields of cell and immune therapy, where DNA, immune molecules, and viruses are all elements to be manipulated, in concert or one at a time.

Furthermore, they have found that neural stems cells can be culled from the patient's bone marrow, thus circumventing ethical and political obstacles to neural stem cell therapy as well as problems with immune rejection that sometimes arise when researchers must employ embryonic stem cell lines.

The proposed clinical trial, in which researchers would use CRISPR to engineer immune cells to fight cancer, won approval from the Recombinant DNA Advisory Committee (RAC) at the U.S. National Institutes of Health, a panel that has traditionally vetted the safety and ethics of gene therapy trials funded by the U.S. government and others.

Plasma therapy is not high risk, but it is logistically difficult to obtain enough plasma from immune patients, which is why it is useful only as a last resort.

Provide example data from experiments using PD - L1 positive tumors and a cancer cell - line engraftment into a humanized mouse model that was used to test anti-PD1 immune therapy

What's more, Discher says, unpublished work from his lab suggests that adding the molecular passports to viruses that deliver genes in gene therapy also helps them avoid immune detection.

Orchestrating a successful immune attack against tumors has proven difficult so far, but a new study from MIT suggests that such therapies could be improved by simultaneously activating both arms of the immune system.

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

And, in fact, these doctors and researchers are finding incredible success with this strategy; for example, PD - 1 inhibitors remove this «cloak» that cancers use to hide from the immune system, and CAR - T cell therapies use specially engineered T - cells to seek cancer - specific proteins and destroy the cancer cells to which they are attached.

Two teams of scientists suggest that activating immune cells in fat can convert the tissue from a type of fat that stores energy to one that burns it, opening up potential new therapies for obesity and diabetes.

If CTL019 is approved, the Swiss pharmaceutical giant plans to dole it out from about 30 preapproved sites, each trained in the multi-step process of harvesting cells, handling the product, and treating patients for the feverish and often life - threatening immune response that usually accompanies CAR - T therapy.

Current therapies to treat pathological inflammation generally focus on quieting the overactive immune response, but in suppressing the immune system, patients are vulnerable to severe infections arising from other sources.

Over the past two decades, the field has started to move from chemotherapy and radiation to targeted monoclonal antibodies and, now, to therapies that activate a patient's own immune system to fight cancer.

Researchers found the gene therapy approach had stronger results when used in combination with either depletion of immunosuppressive cells from the tumor mass or with immune checkpoint blockade.

The results drew attention in part because they come from the lab of James Wilson at the University of Pennsylvania, who led a 1999 trial in which a teenager died from an immune reaction to a different gene therapy vector.

During her graduate training, she discovered that normal bacteria living on our skin educate the immune system and help protect us from harmful pathogens, opening the door for microbiota - based therapies in the skin.

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

Scientists from VIB and KU Leuven, together with colleagues from the University of California and the Swiss Institute for Experimental Cancer Research have demonstrated that, anti-angiogenic therapy can improve immune boosting treatments.

This makes CAR - T therapies very expensive, and it is not always possible to extract enough immune cells from very young or ill patients for the technique to work.

But if the immune system is involved in the new - found problems, it provides additional impetus to develop «personalised» therapies, in which neurons are grown from a patient's own cells, and so should be less likely to provoke an immune reaction.

Early in - the - body gene therapies used a virus called adenovirus — the virus behind the common cold — but the agent can cause an immune response from the body, putting a patient at risk of further illness.

Other blood disorders that have shown significant benefit from targeted gene therapy in small trials include hemophilia (specifically, factor IX deficiency), severe beta - thalassemia (deficiency for the adult beta - globin gene) and leukemia, where the patient's immune cells were treated to enable them to recognize cancer cells and destroy them.

Geneva, Switzerland, 26 March 2014 — A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

«Brain immune system is key to recovery from motor neuron degeneration: Results in study point to new approaches for ALS therapy.»

The authors noted: «From this perspective, by strengthening tumor - associated immune responses, targeting [regulatory T cell] autophagy could act in synergy with strategies that block autophagy in tumor cells for added benefits in cancer therapy.»

Purpose: The development of the UNC Immuno - Oncology Patient Centered Translational Research (IMPACT) Biorepository involves the collection of tumor tissue and blood, as well as data (e.g., demographic, clinical, questionnaire) from patients attending Oncology Clinics at UNC Hospital and undergoing immune therapy through participation in a Merck IT trial at UNC.

Based on findings from this study, therapies might eventually be designed to modulate the immune system in order to prevent vision loss and blindness in glaucoma patients.

ViaCyte's PEC - Encap ™ (also known as VC - 01) product candidate delivers the same cell therapy as PEC - Direct but uses a proprietary device called the Encaptra ® Cell Delivery System that is designed to protect the cells from the patient's immune system.

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

The researchers hypothesized that antibiotics might even have an effect 60 days from start of therapy with immune checkpoint inhibitors.

The first diseases which benefited from gene therapy were rare genetic diseases in which the gene responsible had been identified, in particular severe immune deficiencies

The patients selected for immune therapies might have differed from those selected not to have immune therapies.

GigaGen is a biopharmaceutical company that develops novel antibody therapies derived from immune repertoires.

The findings have implications for the design of cancer vaccines and what are called adoptive T cell therapies; when T cells are collected from a patient and grown in the laboratory, increasing in number before they are given back to the patient to help the immune system fight disease.

Such an immunological exemption could alleviate many concerns about using cells for therapy that don't exactly match the recipient's immune system - such as existing embryonic stem cell lines that are not directly derived from the recipient.

Although researchers are excited about the potential to use CRISPR to create therapies from people's own blood, immune, and stem cells, thousands more genetic conditions affect everything else.

Thus, there is a compelling need to better identify and select patients who may benefit from such immune therapies.

According to Bluestone, «The Immune Tolerance Network hopes this breakthrough will act as a launch pad for further advances that will allow us to free transplant recipients from the immune suppressive therapies.»